To assess whether CD9 EV can serve as biomarker in prostate cancer, we examined the level of CD9 positive and CD63 positive EV in prostate cancer in plasma derived from prostate cancer patients (n=6) and benign prostate hyperplasia (BPH) patients (n=10). This evidence concerns the gene CD63 and benign prostatic hyperplasia.